Bigfoot Biomedical


Bigfoot Biomedical, Inc. is a medical technology startup headquartered with almost 130 employees as of 2019, in Milpitas, California. It is founded by Jeffrey Brewer, Bryan Mazlish, and Lane Desborough.

History

The company began in 2011 when founder Bryan Mazlish’s son was diagnosed with type 1 diabetes. Mazlish developed a control algorithm to drive the first automated artificial pancreas device for his wife and son.
In late 2014, Mazlish joined with Brewer and Desborough to form Bigfoot Biomedical in order to scale and commercialize the technology.
In January 2017, it was reported that Bigfoot Biomedical had received an investment from the Juvenile Diabetes Research Foundation.
In June 2017, the team from Patients Pending LTD, makers of the Timesulin smart insulin pen, joined Bigfoot Biomedical to lead the development of a smart pen solution for people utilizing multiple daily injections to manage their diabetes.

Acquisitions

In May 2015, Bigfoot acquired the assets of Asante Solutions, former manufacturer of the Snap insulin pump. In June 2015, Bigfoot announced a development agreement with Dexcom, securing the technology needed for the continuous glucose monitoring component of the system.
In June 2017, Bigfoot acquired London-based startup Patients Pending, LTD to assist with the development of an insulin pen product.

Development timeline

Bigfoot Biomedical’s first clinical trial enrolled its first patients in 2016. In December 2017, the company closed a Series B funding round and announced plans to begin clinical trials for an automated insulin delivery system in 2018.